Skip to main content

26-05-2022 | Diabetes | News | Article

News in brief

Real-world support for adding Gla-300 to GLP-1 receptor agonists in type 2 diabetes

Author: Alba Ruzafa

medwireNews: The addition of insulin glargine 300 units/mL (Gla-300) to glucagon-like peptide (GLP)-1 receptor agonist therapy in people with type 2 diabetes results in improved glycemic control without increasing risk for hypoglycemia, suggest findings from the real-world DELIVER-G study.

“This is highly clinically relevant in the context of [people with type 2 diabetes] starting with GLP-1 [receptor agonists] and adding [basal insulin], as most previous studies have assessed the addition of GLP-1 [receptor agonists] to [basal insulin] therapy,” say Timothy Bailey (AMCR Institute, Escondido, California, USA) and fellow authors.

The retrospective study, published in Diabetes, Obesity and Metabolism, included data from 271 insulin-naïve people (mean age 57.9 years) on daily or weekly GLP-1 receptor agonist therapy who required treatment intensification and initiated Gla-300 between 2015 and 2019.

After a 6-month follow-up period, there was a significant reduction in mean glycated hemoglobin (HbA1c), from 9.16% (77 mmol/mol) to 8.19% (66 mmol/mol), with the addition of Gla-300. This reduction was irrespective of daily or weekly GLP-1 receptor agonist use or HbA1c level at baseline.

There was also a significant increase in the percentage of individuals who achieved HbA1c control during the follow-up period compared with baseline, with an increase of 17.34 percentage points for a target of under 7% (53 mmol/mol) and 31.73 percentage points for under 8% (64 mmol/mol).

The team says that there were no changes in the overall incidence or event rate of hypoglycemia after adding Gla-300.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

Diabetes Obes Metab 2022; doi:10.1111/dom.14739